Pulmonx Partners with American Lung Association to Launch New Educational Initiatives for COPD Patients and Providers
Pulmonx (Nasdaq: LUNG) and the American Lung Association are expanding their partnership with two new educational initiatives for severe COPD and emphysema patients. The programs include patient stories on the EACH BREATH blog in November 2024 featuring experiences with endobronchial valve (EBV) treatment, and an 'Ask the Expert' Q&A session with a pulmonologist in January on the Lung Association's online communities. The collaboration aims to increase awareness about Zephyr® Endobronchial Valve therapy and provide educational resources for patients and healthcare providers dealing with COPD, which remains the third leading cause of death worldwide according to WHO.
Pulmonx (Nasdaq: LUNG) e l'American Lung Association stanno ampliando la loro collaborazione con due nuove iniziative educative per pazienti con BPCO severa ed enfisema. I programmi includono storie di pazienti sul blog EACH BREATH nel novembre 2024 che presenteranno esperienze con il trattamento con valvole endobronchiali (EBV), e una sessione di domande e risposte 'Chiedi all'Esperto' con un pneumologo a gennaio nelle comunità online dell'Associazione. La collaborazione mira ad aumentare la consapevolezza riguardo alla terapia con Zephyr® Endobronchial Valve e a fornire risorse educative per pazienti e fornitori di assistenza sanitaria che si occupano di BPCO, che rimane la terza causa di morte nel mondo secondo l'OMS.
Pulmonx (Nasdaq: LUNG) y la American Lung Association están ampliando su colaboración con dos nuevas iniciativas educativas para pacientes con EPOC severa y enfisema. Los programas incluyen historias de pacientes en el blog EACH BREATH en noviembre de 2024 que destacarán experiencias con el tratamiento con válvula endobronquial (EBV), y una sesión de preguntas y respuestas 'Pregúntale al Experto' con un neumólogo en enero en las comunidades en línea de la Asociación. La colaboración busca aumentar la concienciación sobre la terapia con Zephyr® Endobronchial Valve y proporcionar recursos educativos para pacientes y proveedores de atención médica que enfrentan la EPOC, que sigue siendo la tercera causa de muerte en el mundo según la OMS.
Pulmonx (Nasdaq: LUNG)와 American Lung Association은 중증 COPD 및 폐기종 환자를 위한 두 개의 새로운 교육 이니셔티브로 파트너십을 확대하고 있습니다. 이 프로그램에는 2024년 11월 EACH BREATH 블로그에 실릴 환자 경험담과 1월에 폐 전문가와의 '전문가에게 물어보기' Q&A 세션이 포함됩니다. 이 협력의 목표는 Zephyr® Endobronchial Valve 치료에 대한 인식을 높이고 COPD를 다루는 환자 및 의료 제공자에게 교육 자료를 제공하는 것입니다. COPD는 WHO에 따르면 여전히 전 세계에서 세 번째로 큰 사망 원인입니다.
Pulmonx (Nasdaq: LUNG) et l'American Lung Association étendent leur partenariat avec deux nouvelles initiatives éducatives pour des patients atteints de BPCO sévère et d'emphysème. Les programmes incluent des histoires de patients sur le blog EACH BREATH en novembre 2024 mettant en lumière des expériences avec le traitement par valve endobronchiale (EBV), et une session de questions-réponses 'Demandez à l'Expert' avec un pneumologue en janvier dans les communautés en ligne de l'Association. Cette collaboration vise à accroître la sensibilisation concernant la thérapie Zephyr® Endobronchial Valve et à fournir des ressources éducatives pour les patients et les professionnels de la santé traitant la BPCO, qui reste la troisième cause de décès dans le monde selon l'OMS.
Pulmonx (Nasdaq: LUNG) und die American Lung Association erweitern ihre Partnerschaft mit zwei neuen Bildungsinitiativen für Patienten mit schwerer COPD und Emphysem. Die Programme beinhalten Patientengeschichten auf dem EACH BREATH Blog im November 2024, die Erfahrungen mit der endobronchialen Ventilbehandlung (EBV) vorstellen, sowie eine 'Frag den Experten' Q&A-Session mit einem Pneumologen im Januar in den Online-Communities der Lung Association. Die Zusammenarbeit zielt darauf ab, das Bewusstsein für die Zephyr® Endobronchial Valve Therapie zu erhöhen und Bildungsressourcen für Patienten und Gesundheitsdienstleister bereitzustellen, die sich mit COPD befassen, die laut WHO die dritthäufigste Todesursache weltweit bleibt.
- Strategic partnership with American Lung Association strengthens market presence and credibility
- New educational initiatives could drive awareness and adoption of Zephyr Valve therapy
- Expanded access to patient education may lead to increased treatment adoption
- None.
Insights
The partnership between Pulmonx and the American Lung Association, while focused on education and awareness, lacks immediate material impact on the company's financial performance or stock value. The planned initiatives for late 2024 are routine marketing and educational activities that are unlikely to significantly influence near-term revenue or market position.
The collaboration primarily involves content creation through blog posts and Q&A sessions - standard promotional activities that don't represent a substantial business development. While these initiatives may help with long-term patient awareness and adoption of the Zephyr Valve, they don't constitute a material event that would warrant immediate investor attention.
Two New Programs Aim to Improve Awareness and Support for Patients with Severe COPD/Emphysema
Building on their successful partnership, the two organizations will launch new resources to educate patients and healthcare providers on innovative treatment options like the Zephyr® Endobronchial Valve, a minimally invasive therapy for advanced COPD/emphysema. According to the World Health Organization (WHO), COPD remains the third leading cause of death worldwide, with millions of patients struggling to breathe and maintain quality of life despite medical management.
As part of this collaboration, Pulmonx and the Lung Association will introduce two new programs to empower patients and clinicians:
-
In November 2024, the Lung Association’s EACH BREATH blog will feature stories from two patients with diverse backgrounds who received endobronchial valve (EBV) treatment, sharing their journeys, decisions, and insights on life before and after the procedure.
- In January, a leading pulmonologist will host an “Ask the Expert” session on the Lung Association's supported “Living with COPD” and “Living with Lung Disease” online communities. The Q&A will be archived on the platform as a lasting resource for patients exploring severe COPD/emphysema treatment options.
“We are excited to continue our partnership with the American Lung Association and together build awareness about the life-changing benefits of the Zephyr Valve therapy,” said Steve Williamson, CEO of Pulmonx. “COPD is a debilitating disease. We want patients and their physicians to know that there are treatment options available to help them breathe easier and live more active lives.”
“A COPD diagnosis can be devastating for an individual and their family to hear, but thankfully there are treatment options available to help improve the lives of people living with this disease,” said Deb Brown, Chief Mission Officer of the American Lung Association. “An important part of living with COPD is being educated on the latest treatments and guidelines. The American Lung Association is proud to partner with Pulmonx to further our commitment to support those affected by COPD and offer a variety of resources and information about the disease.”
The Lung Association collaboration will also build upon the existing educational content available to both patients and healthcare professionals, ensuring that those affected by COPD can make informed decisions about their treatment options.
About the American Lung Association
The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic imperatives: to defeat lung cancer; to champion clean air for all; to improve the quality of life for those with lung disease and their families; and to create a tobacco-free future. For more information about the American Lung Association, which has a 4-star rating from Charity Navigator and is a Platinum-Level GuideStar Member, call 1-800-LUNGUSA (1-800-586-4872) or visit: Lung.org. To support the work of the American Lung Association, find a local event at Lung.org/events.
About Zephyr Valves
The Zephyr Endobronchial Valve is a minimally invasive treatment option for severe COPD/emphysema. Zephyr Valves are placed via bronchoscopy to block off a diseased portion of the lung to prevent air from getting trapped and reduce hyperinflation, which allows the healthier lung tissue to expand and take in more air. This results in patients being able to breathe easier, be less short of breath, and have an improvement in their quality of life.1 National and global treatment guidelines for COPD include Endobronchial Valves like Zephyr Valves as a recommended treatment option for patients with severe COPD/emphysema, with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) giving valves an ‘Evidence A’ rating. More than 40,000 patients have been treated with Zephyr Valves worldwide.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX™ Platform and StratX® Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
References
1Criner G et al. Am J Respir Crit Care Med. 2018; 198 (9): 1151–1164.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241119814005/en/
Media Contact:
Marcee Maroney
mmaroney@pulmonx.com
Source: Pulmonx Corporation
FAQ
What new programs is Pulmonx (LUNG) launching with the American Lung Association in 2024?
What is the purpose of Pulmonx (LUNG)'s partnership with the American Lung Association?
When will Pulmonx (LUNG) feature patient stories about EBV treatment on the EACH BREATH blog?
